Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
According to the Exelixis website and the clinical trial listing, this study information was last updated May 2012 and trial is estimated due to be completed December 2012.
Here is the purpose:
"The purpose of this study is to determine whether or not XL184 demonstrates anti-tumor activity in selected tumor types under a randomized discontinuation trial (RDT) design. Subjects who have responded to study drug after 12 weeks of open-label XL184 administration will continue to take XL184. Subjects who are clearly progressing will discontinue study treatment and subjects who demonstrate stable disease will be randomized to either XL184 or placebo. For individual patients, once disease progression is observed, the blind will be broken and subjects who were randomized to placebo will be offered the option to receive open-label XL184. Subjects who progressed while taking XL184 will discontinue study treatment.
Emerging data may support enrollment in an open-label, non-randomized expansion cohort (NRE). There will be NRE cohorts for prostate and ovarian cancers."
Given that cabo was proven effective in MTC it seems that cabo should show results in cancers located in other parts of a person's body.